← Issue №10/ week of Sep 6, 2026/Hepatology

Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=304 · Sep 1, 2026 · J Clin Gastro · IF 2.9

Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.

New evidenceMASLDhealth servicescost-effectiveness
Clinical takeawayAssess comfort and knowledge gaps in weight loss pharmacotherapy for MASLD patients; consider structured education on FDA-approved options (e.g., GLP-1 agonists) if prescribing barriers align with survey findings (lack of training, cost, side-effects).
What it found96% of hepatology/GI providers believe weight loss medications benefit MASLD patients, but 77% rarely/never prescribe them due to low comfort (81%) and lack of knowledge (only 33% correctly identified >50% of FDA-approved weight loss drugs).
ContextConfirms underutilization of weight loss medications in MASLD despite AASLD guidance, highlighting a disconnect between provider beliefs and practice driven by knowledge deficits.
Measured against the standard of care· AASLD 2023 Practice Guidance (with October 2024 resmetirom and November 2025 semaglutide updates) / EASL 2026 holistic guidance on the steatotic liver disease trajectory (JHEP Reports 2026;8(9):101798)

Decision at stakethe use of weight loss medications in MASLD management

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Lifestyle change is still the foundation of MASLD care, and it is graded by goal. For adults with overweight or obesity, sustained loss of ≥5% of body weight reduces liver fat, 7-10% improves steatohepatitis, and ≥10% improves fibrosis. In lean MASLD the target is 3-5% loss. Diet should follow a Mediterranean pattern. Sugar-sweetened beverages are restricted first; fructose and other sugars, refined carbohydrates, saturated fat, ultra-processed food and red or processed meat are also cut. Low-carbohydrate diets or time-restricted eating are acceptable if they keep Mediterranean principles. Patients should do ≥150 min/week of moderate aerobic exercise plus resistance training (resistance work protects against sarcopenia and suits patients who cannot do aerobic exercise) and should cut sedentary time. Any amount of alcohol is treated as potentially hazardous: screen with AUDIT-C, and in compensated advanced chronic liver disease (cACLD) or cirrhosis advise abstinence. Drugs and surgery are added to lifestyle, never substituted for it, and each is limited by disease stage. Resmetirom is approved by the FDA and EMA (EMA in May 2025), with diet and exercise, for noncirrhotic MASH with F2-F3 fibrosis; it is not for cirrhosis. GLP-1 receptor agonists, or dual GIP/GLP-1 agonists, are the preferred class for patients with type 2 diabetes and/or obesity. Semaglutide 2.4 mg has FDA accelerated approval and AASLD November 2025 guidance support for noncirrhotic MASH F2-F3, with cirrhosis excluded first by noninvasive tests. Anti-obesity drugs are not yet recommended in cirrhosis. Pioglitazone is for selected patients, with or without diabetes, with biopsy-proven MASH (AASLD); it is not for all patients with MASLD and should be avoided in cACLD or cirrhosis. Under AASLD 2023, vitamin E 800 IU/day is limited to biopsy-proven MASH without diabetes or cirrhosis; the 2026 EASL guidance does not cover it. Bariatric or metabolic surgery should be discussed at BMI >35 kg/m2 with comorbidity, or ≥40. In compensated cirrhosis it may help carefully selected patients (MELD <12, Child-Pugh A), usually by sleeve gastrectomy, done at high-volume centres if clinically significant portal hypertension (CSPH) is present. It is contraindicated in decompensated cirrhosis. Comorbidity care is part of MASLD treatment: cardiovascular risk, under-prescribed statins (safe in compensated cirrhosis; avoid high doses when decompensated), diabetes, sleep apnea, mental health and sleep, and vaccination.

AASLD 2023 Practice Guidance (with October 2024 resmetirom and November 2025 semaglutide updates) / EASL 2026 holistic guidance on the steatotic liver disease trajectory (JHEP Reports 2026;8(9):101798) · reviewed 2026-10-11 ↗
Im GY … Bansal MB · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues